ABSTRACT
Alpha-1 antitrypsin deficiency is common but underrecognized. Because delayed diagnosis is thought to be associated with adverse outcomes, clinicians are encouraged to follow available guidelines and test for the disease in all symptomatic adults with fixed airflow obstruction. The weight of available evidence supports the biochemical and clinical efficacy of intravenous augmentation therapy. Promising new therapies are being investigated.
Footnotes
Dr. Stoller has disclosed consulting for Arrowhead.
- Copyright © 2016 The Cleveland Clinic Foundation. All Rights Reserved.
- James K. Stoller, MD, MS⇑
- Chair, Education Institute, Cleveland Clinic; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
- ADDRESS:
James K. Stoller, MD, MS, Education Institute, NA2, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; stollej{at}ccf.org
ABSTRACT
Alpha-1 antitrypsin deficiency is common but underrecognized. Because delayed diagnosis is thought to be associated with adverse outcomes, clinicians are encouraged to follow available guidelines and test for the disease in all symptomatic adults with fixed airflow obstruction. The weight of available evidence supports the biochemical and clinical efficacy of intravenous augmentation therapy. Promising new therapies are being investigated.
Footnotes
Dr. Stoller has disclosed consulting for Arrowhead.
- Copyright © 2016 The Cleveland Clinic Foundation. All Rights Reserved.
Jump to section
Related Articles
Cited By...
- No citing articles found.